A randomized controlled trial evaluating the effects of a family-centered HIV care model on viral suppression and retention in care of HIV-positive children in Eswatini

Kim Ashburn, Caspian Chouraya, Philisiwe Khumalo, Lydia Mpango, Nobuhle Mthethwa, Rhoderick Machekano, Laura Guay, Lynne M Mofenson, Kim Ashburn, Caspian Chouraya, Philisiwe Khumalo, Lydia Mpango, Nobuhle Mthethwa, Rhoderick Machekano, Laura Guay, Lynne M Mofenson

Abstract

Introduction: A family-centered care model (FCCM) providing family-based HIV services, rather than separate adult/pediatric services, has been proposed to increase pediatric retention and treatment adherence.

Materials and methods: Eight health-care facilities in the Hhohho region of Eswatini were randomized to implement FCCM (n = 4) or continue standard-of-care (SOC) separate adult/pediatric clinics (n = 4). HIV-positive children and caregivers were enrolled; caregiver interview and child/caregiver chart abstraction were done at enrollment and every three months; pediatric viral load was evaluated at enrollment and every six months through 12 months. Because of study group differences in 12-month viral load data availability (89.4% FCCM and 72.0% SOC children had 12-month viral load), we used three separate analyses to evaluate the effects of FCCM on children's viral suppression (<1,000 copies/mL) and undetectable virus (<400 copies/mL) at 12 months. In the first analysis, all children with missing viral outcome data were excluded from the analysis (modified intent to treat, mITT). The second analysis used inverse probability of missingness weighted logistic regression to estimate the effect of FCCM on 12-month viral outcomes compared to SOC (weighted mITT). For the third approach, missing virologic outcome data were imputed as virologic failure (imputed ITT). We also examined factors associated with viral suppression at 12 months using multivariable logistic regression.

Results: We enrolled 379 HIV-positive children and 363 caregivers. Among all children at enrollment, viral suppression and undetectability was 78.4% and 73.9%, respectively, improving to 90.2% and 87.3% at 12 months. In mITT and weighted mITT analyses, there was no significant difference in children's 12-month viral suppression between FCCM and SOC groups (89.2% and 91.6%, respectively). Using imputed ITT, there was a modest increase in 12-month viral suppression in FCCM versus SOC children (79.7% and 69.8%, respectively, p = 0.051) and 12-month undetectability (78.7% and 65.7%, respectively, p = 0.015). Among the 255 children suppressed at enrollment, more FCCM versus SOC children (98.0% versus 95.3%) were suppressed at 12-months, but this was not statistically significant in mITT or weighted mITT analyses, with a marginally significant difference using imputed mITT analysis (p = 0.042). A higher proportion of children suppressed at enrollment had undetectable viral load at 12 months in FCCM versus SOC children (98.0% versus 92.5%), a statistically significant difference across analytical methods. Among the 61 children unsuppressed at enrollment, achieving suppression was higher among SOC versus FCCM children, but this difference was not statistically significant and included only 38 children; and there were no significant differences in detectable viral load at 12 months. There were no significant differences between study groups in retention or ART adherence at 12 months for children or caregivers. Factors associated with lack of viral suppression/detectability at 12 months included lack of viral suppression at enrollment and having a younger caregiver (age <25 years).

Conclusions: FCCM in Eswatini was associated with a modest increase in viral suppression/undetectability at 12-months; 12-month retention and adherence did not differ by study group for children or caregivers. High levels of suppression and retention in both groups may have limited our ability to detect a difference.

Trial registration: NCT03397420; ClinicalTrials.gov.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. FAM CARE study consort flowchart.
Fig 1. FAM CARE study consort flowchart.
*Randomization was at facility cluster level: 2 clusters assigned to FCCM and 2 clusters assigned to SOC groups. **Each caregiver/family could have more than 1 child. ***Children could have viral load test drawn for study but missed a clinic visit.

References

    1. Swaziland Ministry of Health. Swaziland integrated HIV management guidelines. 2015. .
    1. Joint United Nations Programme on HIV/AIDS Eswatini Factsheet. 2018. .
    1. Government of the Kingdom of Eswatini. Swaziland HIV Incidence Measurement Survey 2 (SHIMS2) 2016–2017. Final Report. Mbabane: Government of the Kingdom of Eswatini; April 2019. .
    1. Leeper S, Montague BT, Friedman JF, Flanagan TP. Lessons learned from family-centered models of treatment for children living with HIV: current approaches and future directions. J Int AIDS Soc. 2010;13(Suppl 2):53. doi: 10.1186/1758-2652-13-S2-S3
    1. Richter L, Beyrer C, Kippax S, Heidari S. Visioning services for children affected by HIV and AIDS through a family lens. J Int AIDS Soc. 2010;13(Suppl 2):I1. doi: 10.1186/1758-2652-13-S2-I1
    1. Luyirka E, Towle MS, Achan J, Muhangi J, Senyimba C, Lule F, et al.. Scaling-up Pediatric HIV Care with an Integrated, Family-Centered Approach: An Observational Case Study from Uganda. PLoS One. 2013;8(8):e69548. doi: 10.1371/journal.pone.0069548
    1. Myer L, Abrams J, Zhang Y, Duong J, El-Sadr WM, Carter RJ. Family matters: co-enrollment of family members into care is associated with improved outcomes for HIV-infected women initiating antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;67(Suppl 4):S243–9. doi: 10.1097/QAI.0000000000000379
    1. Towne-Gold B, Ekouevi DK, Amani-Bosse C, Koné M, Becquet R, Leroy V, et al.. Implementing family-focused HIV care and treatment: the first 2 years’ experience in the mother-to-child transmission-plus program in Abidjan, Cote d’Ivoire. Trop Med Int Health. 2009;14:204–12. doi: 10.1111/j.1365-3156.2008.02182.x
    1. Hosegood V, Madhavan S. Data availability on men’s involvement in families in sub-Saharan Africa to inform family-centered programmes for children affected by HIV and AIDS. J Int AIDS Soc. 2010;13(Suppl 2):S5. doi: 10.1186/1758-2652-13-S2-S5
    1. Betancourt TS, Abrams EJ, McBain R, Smith-Fawzi MC. Family-centered approaches to the prevention of mother to child transmission of HIV. J Int AIDS Soc. 2010;13(Suppl 2):S2. doi: 10.1186/1758-2652-13-S2-S2
    1. CliniTrial, Version 2.0.28. CliniOps Inc. Fremont, California. .
    1. Chouraya C, Ashburn K, Khumalo P, Mpango L, Mthethwa N, Machekano R, et al.. Association of antiretroviral drug regimen with viral suppression in HIV-positive children on antiretroviral therapy in Eswatini. Pediatr Infect Dis J. 2019;38(8):835–9. doi: 10.1097/INF.0000000000002347
    1. Khumalo P, Katirayi L, Ashburn K, Chouraya C, Mpango L, Mthethwa N, et al.. ‘There are no more secrets’: acceptability of a family-centered model of care for HIV-positive children in Eswatini. BMC Health Serv Res 2020;20(1):951. doi: 10.1186/s12913-020-05810-5
    1. Massavon W, Barlow-Mosha L, Mugenyi L, McFarland W, Gray G, Lundin R, et al.. Factors determining survival and retention among HIV-infected children and adolescents in a community-based home care and a facility-based family-centered approach in Kampala, Uganda: a cohort study. ISRN AIDs. 2014;2014:852489. doi: 10.1155/2014/852489
    1. Graves JC, Elyanu P, Schellack CJ, Asire B, Prust ML, Prescott MR, et al.. Impact of a Family Clinic Day intervention on paediatric and adolescent appointment adherence and retention in antiretroviral therapy: a cluster randomized controlled trial in Uganda. PLoS One. 2018;13(3):e0192068. doi: 10.1371/journal.pone.0192068
    1. Van Wyk BE, Kriel E, Mukumbang F. Two-year viral load suppression among adolescents receiving antiretroviral therapy in the Cape Metropole, South Africa, 2013–2015: a retrospective cohort analysis. S Afr Med J. 2020;110(12):1213–17. doi: 10.7196/SAMJ.2020.v110i12.14509
    1. Nabukeera S, Kagaayi J, Makumbi FE, Mugerwa H, Matovu JKB. Factors associated with virological non-suppression among HIV-positive children receiving antiretroviral therapy at the Joint Clinical Research Centre in Lubowa, Kampala, Uganda. PLosOne. 2021;16:e0246140. doi: 10.1371/journal.pone.0246140
    1. Teasdale CA, Sogaula N, Yuengling KA, Wang C, Mutiti A, Arpadi S, et al.. HIV viral suppression and longevity among a cohort of children initiating antiretroviral therapy in Eastern Cape, South Africa. J Int AIDS Soc. 2018;21(8):e25168. doi: 10.1002/jia2.25168
    1. Beima-Sofie K, Brandt L, Hamunime N, Shepherd M, Uusiku J, John-Stewart GC, et al.. Pediatric HIV disclosure intervention improves knowledge and clinical outcomes in HIV-infected children in Namibia. J Acquir Immune Defic Syndr. 2017;75(1):18–26. doi: 10.1097/QAI.0000000000001290
    1. Arrivé E, Dicko F, Amghar H, Aka AE, Dior H, Bouah B, et al.. HIV status disclosure and retention in care in HIV-infected adolescents on antiretroviral therapy (ART) in West Africa. PLoS One. 2012;7(3). e33690. doi: 10.1371/journal.pone.0033690
    1. Atwiine B, Kiwanuka J, Musinguzi N, Atwine D, Haberer JE. Understanding the role of age in HIV disclosure rates for HIV infected children in southwestern Uganda. AIDS Care. 2015;27(4):424–430. doi: 10.1080/09540121.2014.978735
    1. Chaudhury S, Kirk CM, Ingabire C, Mukunsi S, Nyirandagijimana B, Godfrey K, et al.. HIV status disclosure through family-based intervention supports parenting and child mental health in Rwanda. Front Public Health. 2016;4:138. doi: 10.3389/fpubh.2016.00138
    1. Van Rooyen H, Essack Z, Rochat T, Wight D, Knight L, Bland R, et al.. Taking HIV testing to families: designing a family-based intervention to facilitate HIV testing, disclosure, and intergenerational communication. Front Public Health. 2016;4:154. doi: 10.3389/fpubh.2016.00154
    1. Betancourt TS, Ng LC, Kirk CM, Brennan RT, Beardslee WR, Stulac S, et al.. Family-based promotion of mental health in children affected by HIV: a pilot randomized controlled trial. J Child Psychol Psychiatry. 2017;58(8):922–30. doi: 10.1111/jcpp.12729

Source: PubMed

3
Prenumerera